Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax +- rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study
Pirtobrutinib;Venetoclax;Rituximab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax +- rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study ### Output: Pirtobrutinib;Venetoclax;Rituximab